Why the study?
Does high-dose direct renin inhibitor reduce central blood pressure and augmentation index more than standard-dose direct renin inhibitor plus hydrochlorothiazide in patients with essential hypertension?
Does high-dose direct renin inhibitor reduce central blood pressure and augmentation index more than standard-dose direct renin inhibitor plus hydrochlorothiazide in patients with essential hypertension?
In patients with essential hypertension not responding to a standard-dose direct renin inhibitor, up-titrating to a high dose significantly reduced central blood pressure and augmentation index compared to adding a diuretic.
Answers are grounded in this paper and cite their sources.
High-dose direct renin inhibitor may be preferred over adding a diuretic for central blood pressure reduction; extends titration evidence in non-responders.
BACKGROUND: Central blood pressure (CBP) is superior to brachial blood pressure as a predictor of cardiovascular risk in patients with hypertension. There is currently no consensus regarding whether a direct renin inhibitor (DRI) selectively acts on CBP. METHODS: Thirty subjects with essential hypertension who showed a CBP of 140 mm Hg or higher after 12 weeks of treatment with a standard dose of a DRI (150 mg) were analyzed. The patients were randomly divided into 2 groups: the high-dose DRI group (n=15) received 300 mg of DRI per day, and the combination group (n=15) received both the standard dose of the DRI and a diuretic (12.5 mg of hydrochlorothiazide). The systolic blood pressure (SBP), CBP, and the augmentation index (AI) were determined before treatment and after 12 and 24 weeks of treatment. RESULTS: The SBP, CBP and AI were significantly decreased after 12 weeks of treatment with standard dose of the DRI (p<0.05). From 12 to 24 weeks after assignment the SBP and CBP were also significantly decreased in both the high-dose DRI group and the combination group. The high-dose DRI group showed a greater decrease in the CBP, but not in the SBP, than did the combination group (p<0.05). The AI decreased significantly from 12 to 24 weeks in the high-dose DRI group (p<0.05) but not in the combination group (p=0.14). CONCLUSIONS: Treatment with a DRI contributes to a decrease in the CBP and AI, and high-dose DRI therapy leads to a further decrease in the CBP and AI.
No takes yet. Share an insight, caveat, or question.
Kubota et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: